HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low fibrosis biomarker levels predict cardiac resynchronization therapy response.

Abstract
Cardiac fibrosis is associated with heart failure and poor prognosis. Fibrosis biomarkers have been poorly evaluated as a tool to predict cardiac resynchronization therapy (CRT) response generating conflicting results. The present study assessed the predictive value of cardiac fibrosis biomarkers on CRT response. Patients underwent clinical examination, echocardiography and blood fibrosis biomarker evaluation prior to CRT implantation. At six months, a positive response to CRT was defined by a composite endpoint of no death or hospitalization for heart failure, and presence of left ventricular (LV) reverse remodeling (decrease in LV end-systolic volume ≥15%). Sixty patients were included in a multicenter study. At 6 months, 38 were positive responders to CRT and reached the response criteria (63%). Compared to non-responders, CRT responders displayed lower concentration levels of the fibrosis biomarkers procollagen type I C-terminal propeptide [PICP 135[99-166] ng/ml vs. 179[142-226]ng/ml, p = 0.001)] and procollagen type III N-terminal propeptide [PIIINP 5.50[3.66-8.96] ng/ml vs. 8.01[5.01-11.86]ng/ml, p = 0.014)] at baseline. In multivariate analysis, a PICP ≤ 163 ng/ml was associated with a positive CRT response [OR = 7.8(1.3-46.7), p = 0.023] independently of the presence of LBBB, QRS duration, LV lead position or non-ischemic cardiomyopathy. Altogether, the present findings show that a lower degree of cardiac fibrosis is associated with a positive response after CRT implantation. PICP evaluation before CRT implantation could help improve patient selection.
AuthorsGrégoire Massoullié, Vincent Sapin, Sylvain Ploux, Patrick Rossignol, Aurélien Mulliez, Frédéric Jean, Pierre-Yves Marie, Charles Merlin, Bruno Pereira, Marius Andronache, Pascal Motreff, Xavier Chabin, Jean-Marc Sellal, Bernard Citron, Jean-René Lusson, Charles Vorilhon, Guillaume Clerfond, Pierre Bordachar, Faiez Zannad, Romain Eschalier
JournalScientific reports (Sci Rep) Vol. 9 Issue 1 Pg. 6103 (04 15 2019) ISSN: 2045-2322 [Electronic] England
PMID30988339 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Peptide Fragments
  • Procollagen
  • procollagen Type III-N-terminal peptide
  • procollagen type I carboxy terminal peptide
Topics
  • Aged
  • Biomarkers (blood)
  • Cardiac Resynchronization Therapy
  • Female
  • Fibrosis
  • Heart Failure (pathology, therapy)
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments (blood)
  • Procollagen (blood)
  • Prospective Studies
  • Treatment Outcome
  • Ventricular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: